MOZART: Phase II Trial of Monalizumab, Durvalumab, and Platinum-based Chemotherapy for First-Line Treatment of Extensive Stage SCLC

被引：0
|
作者：
Mamdani, H. [1 ]
Kim, S. [1 ]
Gentzler, R. [2 ]
Furqan, M. [3 ]
Shields, M. D. [4 ]
Jalal, S. I. [4 ]
机构：
[1] Wayne State Univ, Barbara Ann Karmanos Canc Inst, Detroit, MI USA
[2] Univ Virginia, Charlottesville, VA USA
[3] Univ Iowa, Iowa City, IA USA
[4] Indiana Univ, Indianapolis, IN 46204 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Small cell lung cancer; Monalizumab; Extensive stage;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.13A.03
引用
收藏
页码：S207 / S207
页数：1
相关论文
共 50 条
  • [41] A phase 3, randomized study of first-line durvalumab (D) ± tremelimumab (T) plus platinum-based chemotherapy (CT) vs CT alone in extensive disease small-cell lung cancer (ED-SCLC): Caspian
    Paz-Ares, Luis G.
    Jiang, Haiyi
    Huang, Yifan
    Dennis, Phillip A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [42] Clinical outcomes for advanced thymoma patients receiving platinum-based chemotherapy as first-line treatment
    Hao, Y.
    Sun, W.
    Zeng, X.
    Shi, Z.
    Wang, W.
    Xu, C.
    Song, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S157 - S157
  • [43] A RANDOMIZED PHASE II TRIAL OF CELECOXIB COMBINED WITH PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE AND WITH ICOTINIB AS SECOND-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER
    Chu, Tianqing
    Han, Baohui
    Jiang, Liyan
    Zhong, Hua
    Gu, Aiqin
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S612 - S613
  • [44] Maintenance durvalumab after first-line platinum-based chemotherapy in advanced oesophago-gastric (OG) adenocarcinoma: Results from the PLATFORM trial.
    Fong, Caroline
    Patel, Bijal
    Peckitt, Clare
    Bourmpaki, Elli
    von Loga, Katharina
    Begum, Ruwaida
    Davidson, Michael
    Anandappa, Gayathri
    Cafferkey, Catherine
    Watkins, David J.
    Rao, Sheela
    Waddell, Tom
    Wadsley, Jonathan
    Coxon, Fareeda
    Roques, Tom
    Morgan, Carys
    Rees, Charlotte
    Starling, Naureen
    Chau, Ian
    Cunningham, David
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [45] Durvalumab ± tremelimumab plus platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study
    Paz-Ares, L.
    Chen, Y.
    Reinmuth, N.
    Hotta, K.
    Trukhin, D.
    Statsenko, G.
    Hochmair, M. J.
    Ozguroglu, M.
    Ji, J. H.
    Voitko, O.
    Poltoratskiy, A.
    Verderame, F.
    Havel, L.
    Bondarenko, I.
    Losonczy, G.
    Conev, N. V.
    Broadhurst, H. L.
    Dalvi, T.
    Jiang, H.
    Goldman, J. W.
    ANNALS OF ONCOLOGY, 2021, 32 : S1338 - S1338
  • [46] Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
    Grande, Enrique
    Bamias, Aristotelis
    Galsky, Matthew D.
    Kikuchi, Eiji
    Davis, Ian D.
    Arranz, Jose Angel
    Kalebasty, Arash Rezazadeh
    del Muro, Xavier Garcia
    Park, Se Hoon
    De Giorgi, Ugo
    Alekseev, Boris
    Mencinger, Marina
    Izumi, Kouji
    Puente, Javier
    Li, Jian-Ri
    Bernhard, Sandrine
    Nicholas, Alan
    Telliez, Julie
    De Santis, Maria
    EUROPEAN UROLOGY OPEN SCIENCE, 2023, 58 : 28 - 36
  • [47] RANDOMIZED PHASE II STUDY OF BELOTECAN OR TOPOTECAN CHEMOTHERAPY AS SECOND-LINE CHEMOTHERAPY AFTER PLATINUM-BASED FIRST-LINE CHEMOTHERAPY FOR SMALL CELL LUNG CANCER
    Yoon, S.
    Lee, D. H.
    Choi, C.
    Lee, J. C.
    Lee, J. S.
    Kim, S.
    ANNALS OF ONCOLOGY, 2014, 25
  • [48] EFFICACY AND SAFETY OF FIRST-LINE PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH POST-OPERATIVE RECURRENCE AFTER PLATINUM-BASED ADJUVANT CHEMOTHERAPY
    Muraki, K.
    Imai, H.
    Shukuya, T.
    Ohhashi, R.
    Koyama, R.
    Mori, T.
    Murakami, H.
    Takahashi, T.
    Yamamoto, N.
    Takahashi, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 148 - 148
  • [49] A Phase 3, randomized study of first-line durvalumab (D) plus /- tremelimumab (T) plus platinum-based chemotherapy (CT) vs CT alone in extensive disease small-cell lung cancer (ED-SCLC): CASPIAN
    Alt, J.
    Bischoff, H. G.
    Laack, H-E
    Leistner, R. D.
    Panse, J.
    Reinmuth, N.
    Schulz, C.
    Grohe, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 103 - 103
  • [50] MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC
    Peters, S.
    Antonia, S.
    Goldberg, S. B.
    Heymach, J. V.
    Kim, E. S.
    Nakagawa, K.
    Papadimitrakopoulou, V.
    Mukhopadhyay, P.
    McIntosh, S.
    Rizvi, N. A.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S139 - S140
12345